Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care

Related

• Clinical Journal of the American Society of Nephrology·4 Oct 2026

  SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

• Diabetes, Obesity & Metabolism·4 Oct 2026

  GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

• Diabetes & Vascular Disease Research·4 Oct 2026

  SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

• The American Journal of Cardiology·8 Oct 2026

  Drug class linked to fewer deaths or complications in kidney disease